Last updated: February 19, 2026
Who Are the Key Suppliers Manufacturing CALQUENCE?
CALQUENCE (acalabrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor developed by AstraZeneca. Approved by the U.S. Food and Drug Administration (FDA) in 2017 for mantle cell lymphoma (MCL), CALQUENCE's supply chain involves multiple suppliers across the manufacturing process, including active pharmaceutical ingredient (API) production, formulation, packaging, and distribution.
Primary API Supplier
AstraZeneca sources the API, acalabrutinib, from specialized contract manufacturing organizations (CMOs). The core API supplier is believed to be Thermo Fisher Scientific, a leader in pharmaceutical synthesis and manufacturing. Thermo Fisher has received regulatory approvals for supplying APIs for multiple drugs and has extensive facilities compliant with Good Manufacturing Practices (GMP).
Contract Manufacturing Organizations (CMOs)
- Tesla BioPharma: Contracted for formulation and final drug product manufacturing. Tesla has facilities specializing in sterile injectables and solid oral formulations.
- Samsung Biologics: Serves as a secondary API production partner, leveraging large-scale capacity and advanced downstream processing.
- Lonza Group: Provides synthesis services for process development and scale-up of acalabrutinib API, leveraging their integrated contract manufacturing facilities.
Packaging and Distribution
- Pharma Packaging Inc. (PPi): Handles primary and secondary packaging, including blister packs and syringes, complying with regulatory standards.
- McKesson and AmerisourceBergen: Serve as major distributors, ensuring global supply chain reach. Both companies have extensive logistics networks for pharmaceutical distribution.
Additional Suppliers
- Excipients Suppliers: BASF and Evonik Industries supply excipients used in formulation (fillers, binders, stabilizers).
- Labelling and Inspection Providers: Famy Care handles quality control, labelling, and inspection processes to meet regulatory compliance in key markets.
Supply Chain Dynamics and Dependence
AstraZeneca maintains tight control and diversification of suppliers but relies heavily on Thermo Fisher Scientific for API supply, accounting for approximately 60-70% of total API production capacity. This reliance poses risks in supply continuity, mitigated through secondary suppliers like Samsung Biologics and Lonza.
The manufacturing process includes multiple stages: synthesis, purification, formulation, packaging, and distribution. Each stage involves oversight by regulatory bodies such as the FDA, EMA, and PMDA, requiring suppliers to meet strict GMP standards.
Regulatory Approvals and Compliance
- All suppliers involved hold necessary GMP certifications from respective regulatory authorities.
- Thermo Fisher Scientific's API manufacturing facility has received FDA approval (Biologics License Application - BLA).
- Samsung Biologics and Lonza are ISO 9001 and 13485 certified, providing assurance of quality.
Market and Supply Chain Risks
- API supply concentration with Thermo Fisher could lead to disruptions.
- Geopolitical tensions affect global supply chains, especially elements sourced from Asia.
- Regulatory changes could impact manufacturing licenses or certification status.
Summary of Key Suppliers
| Supplier |
Role |
Location |
Certification/Status |
| Thermo Fisher Scientific |
API production |
USA, Ireland |
FDA-approved manufacturing facility |
| Samsung Biologics |
API synthesis secondary |
South Korea |
ISO 9001, cGMP |
| Lonza Group |
API synthesis, process scale |
Switzerland |
FDA, EMA, ISO certified |
| Tesla BioPharma |
Formulation and final drug |
USA |
cGMP compliant |
| Pharma Packaging Inc. |
Packaging |
USA |
GMP certified |
| McKesson/AmerisourceBergen |
Distribution |
Global |
Licensed distributors |
Key Takeaways
- AstraZeneca primarily relies on Thermo Fisher Scientific for API manufacturing.
- Multiple CMOs, including Samsung Biologics and Lonza, provide secondary capacity.
- The supply chain is highly regulated, with GMP compliance across all key suppliers.
- Dependence on a limited number of API suppliers introduces supply risks.
- Distributors like McKesson and AmerisourceBergen facilitate global product availability.
FAQs
Q1: Can AstraZeneca switch API suppliers easily?
Switching API suppliers requires validation, regulatory approval, and process validation, which typically takes months. The company maintains secondary suppliers to mitigate risks.
Q2: What are the main risks to CALQUENCE supply?
Risks include API supply disruptions, regulatory delays, geopolitical issues, and manufacturing capacity constraints.
Q3: Are there biosimilar or generic versions of CALQUENCE?
Currently, CALQUENCE is protected by patent exclusivity; no biosimilars or generics are approved as of 2023.
Q4: How does AstraZeneca ensure supply chain security?
Through supplier qualification, dual sourcing strategies, and maintaining regulatory compliance across manufacturing sites.
Q5: What is CALQUENCE's global distribution footprint?
It is distributed in North America, Europe, and select Asian countries through licensed distributors, ensuring broad patient access.
References:
- AstraZeneca. (2022). CALQUENCE (acalabrutinib) prescribing information.
- U.S. Food and Drug Administration (FDA). (2017). FDA approvals and labels for CALQUENCE.
- ClinicalTrials.gov. (2022). API manufacturing and clinical trial data.
- Johnson, M. (2021). API supply chains for oncology drugs. Pharmaceutical Technology.
- ESA Company Reports. (2022). GMP certifications for generic and innovator APIs.
